L2 Lipopeptide Vaccine for Prevention of Human Papillomavirus Infection

Abstract (Set) Human papillomavirus (HPV) infections are the most common sexually transmitted infection in the United States. Infection by over 15 different oncogenic HPV genotypes is a cause of cervical cancer. Therefore, a low-cost, broadly protective vaccine that can be delivered without needles is urgently needed. JHU scientists have discovered a novel lipopeptide derived from the minor capsid protein L2 of medically-significant HPV genotype and produced by direct synthesis as an approach to generate broadly protective vaccines against HPV-related disease. The L2 lipopeptide can be chemically synthesized at low cost. It can be delivered intranasally without the use of needles. Description (Set) • A broadly protective vaccine against HPV.
• Can be delivered without needles.
• Can be chemically synthesized at low cost. Proposed Use (Set) A broadly protective vaccine against Human papillomavirus infection and any of its sequelae

Inventor(s): Roden, Richard B. S. ,Alphs, Hannah ,Gambhira, Ratish

Type of Offer: Licensing



« More Medical Patents

---